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a  b  s  t  r  a  c  t
 T cells  constitute  a sizeable  and  non-redundant  fraction  of  the total  T  cell  pool  in all  jawed  vertebrates,
but  in  contrast  to conventional   T cells  they  are  not  restricted  by  classical  MHC  molecules.  Progress
in  our  understanding  of  the  role  of  T cells  in  the immune  system  has  been  hampered,  and  is  being
hampered,  by  the  considerable  lack of  knowledge  regarding  the  antigens   T cells respond  to.  The  past
few  years  have  seen  a wealth  of  data  regarding  the TCR  repertoires  of  distinct   T cell  populations  and  a
growing  list  of  conﬁrmed  and  proposed  molecules  that  are  recognised  by  T cells  in different  species.
Yet,  the  physiological  contexts  underlying  the  often  restricted  TCR  usage  and  the  chemical  diversity
of   T  cell  ligands  remain  largely  unclear,  and  only  few  structural  studies  have  conﬁrmed  direct  ligandigand recognition
nnate immunity
daptive immunity
tress immune surveillance
nfection
ancer
recognition  by the  TCR. We  here  review  the latest  progress  in  the  identiﬁcation  and  validation  of putative
  T cell  ligands  and  discuss  the  implications  of  such  ﬁndings  for  T cell  responses  in  health  and  disease.
©  2017  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).mmunotherapy
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. Introduction: how does it feel, like a complete unknown?
The past three decades have witnessed remarkable progress
n our understanding of antigen presentation and the molecu-
ar and cellular mechanisms underlying antigen-speciﬁc  T cell
esponses, as summarised in this special issue of Seminars in Cell
nd Developmental Biology. The outstanding importance of antigen
resentation for biomedical science as a whole of some of the major
ontributions in the ﬁeld is best illustrated by the awarding of the
obel Prizes in Physiology or Medicine for the discovery of the
ajor histocompatibility complex (MHC) in 1980, the principles
f overcoming organ transplant rejection in 1990, the deﬁnition
f MHC  restricted immune responses in 1996, and the discovery
f dendritic cells (DCs) and their role in adaptive immunity in
011. Such knowledge is now successfully exploited in the clinic
or antigen-speciﬁc vaccination against infectious diseases and can-
er, and for the induction of immune tolerance in autoimmune
isorders.
Set apart from MHC  restricted  T cells,  T cells constitute
 sizeable and non-redundant fraction of the total T cell pool in all
awed vertebrates. Although typically portrayed as a minor lym-
hocyte subset in humans and rodents,  T cells may  actually
xceed >50% of all T cells and thus constitute the dominant T cell
opulation in certain tissues and species, for instance in ruminants
nd chicken (especially in early life), in the mouse epidermis, and in
uman blood during microbial infection [1–3]. Moreover,  T cells
ave been implicated in a wide range of immunological scenarios
n the healthy organism and in disease [4–6]. However, progress in
ur understanding of the role of  T cells in the immune system has
een hampered, and is being hampered, by the considerable lack of
nowledge regarding the structures  T cells respond to, despite
xtensive efforts by numerous laboratories since the discovery of
 T cells in the mid-1980s [7]. In stark contrast to the well-deﬁned
resentation of peptide antigens to CD4+ and CD8+  T cells via
HC  class II and class I molecules, respectively, and the elucidation
f additional pathways leading to the presentation of lipids and
etabolites via CD1 family members and the MHC-related protein
R1  [8], there is no consensus as to the class of ‘antigens’  T
ells recognise, and how such antigens are presented. In fact, there
s only little evidence that antigens are indeed ‘presented’ to  T
ells in the classical sense.
. The role of the  TCR: blowin’ in the wind
.1. Ligand recognition during thymic selection
As in  T cells, a diverse TCR repertoire can be generated in 
 cells by variable (V) gene combinations and formation of V(D)J
unctions [6].  T cells are conspicuously different at the TCR level
rom conventional  T cells in that they display characteristic TCR
iases with regard to V usage and/or complementarity determining
egion 3 (CDR3) sequences, depending on the anatomical location
nd physiological context. Of note, there are no obvious homolo-
ies between human and mouse V gene sequences, thus making it
ifﬁcult to compare mouse and human  T cells based on their TCR
sage [11,12]. In mice, distinct waves of  T cell subsets expressing
haracteristic V and V combinations populate different organs
uring embryonic development and display distinct effector func-
ions [4–6]. These early  T cells in fact express invariant  TCRs,
hereas later on in development the TCRs possess polyclonal CDR3
equences but typically still show biased V chain usages [14].Please cite this article in press as: D. Vermijlen, et al.,  T cell respon
Biol (2018), https://doi.org/10.1016/j.semcdb.2017.10.009
Representing the prime example of such an invariant TCR, the
rst  T cells to emerge in the murine foetal thymus express a ﬁxed
CR composed of invariant V5J1C1  and invariant V1D2J2
hains (V5/V1  in short; nomenclature according to Heilig and PRESS
opmental Biology xxx (2018) xxx–xxx
Tonegawa [13]) and migrate to the skin epidermis where they
become dendritic epidermal T cells (DETCs) [14]. The next such
population arising in the thymus actually carries the same canon-
ical V1D2J2 chain yet combined with an invariant V6J1C1
chain (V6/V1  T cells), and seeds the skin dermis and other tis-
sues [14]. Thus, separate  T cell subsets may  occupy different
sites even within the same organ.
The biases in TCR usage depending on anatomical locations and
functions strongly indicate a direct involvement of the TCR, and
consequently of tissue-restricted self or non-self ligands, in shaping
different  T cell compartments and in local immune surveil-
lance and/or pathogen sensing. However, it has been suggested
that  T cells may  also exert major functions in an innate-like, TCR
independent manner [15,16]. Such ﬁndings seemingly question the
physiological relevance of the  TCR and the corresponding  T
cell ligands in certain contexts although it may  be technically chal-
lenging to exclude simultaneous TCR triggering depending on the
experimental conditions [17]. There is also apparently conﬂicting
evidence for the precise role of the  TCR in thymic development,
especially with regard to the requirement of a possible ligand-
dependent positive selection and developmental programming of
 T cells [18]. Clearly, the role of the  TCR is different from
the ‘conventional’ selection of MHC  restricted CD4+ and CD8+ T
cells, and this role appears to vary greatly across different  T
cell subsets [6,19–23]. Indeed, in contrast to  T cells that leave
the thymus as naive antigen-inexperienced T cells, functional mat-
uration and pre-programming of  T cells may  already occur in
the thymus [24,25], with different  T cell subsets as marked by
particular V usage showing distinct TCR signal strength require-
ments for their functional differentiation [18,23]. However, the
fact that V5/V1 and V6/V1 TCR sequences are present at the
DNA level in the foetal thymus of TCR−/− mice suggests that the
corresponding TCR rearrangements are not necessarily a result of
clonal thymic selection [26]. Other cells in the thymus, such as
medullary thymic epithelial cells (mTECs), may  play an impor-
tant role in  T cell development. Indeed, murine V5/V1 T cell
progenitors contribute to the emergence of Aire+ mTECs that in
turn foster Skint-1-dependent DETC progenitor maturation and the
emergence of an invariant DETC V5V1 repertoire [27]. In addi-
tion, Aire may  have an inhibitory role in the development of IL-17
producing invariant V6/V1 T cells in the mouse [28].
The majority of human blood  T cells express a V9JPC1
chain paired with a V2 chain (V9/V2  T cells; nomenclature
according to Lefranc & Rabbitts [29]), while  T cells in tissues
such as the intestine, skin or liver are enriched in other V and/or
V chains [4–6]. The high prevalence of V9/V2 T cells show-
ing a restricted TCR repertoire in the adult peripheral blood has
been attributed to extrathymic expansion in response to environ-
mental and pathogenic microbes [30], with a striking prevalence
of a single germline-encoded CDR3 sequence in adults [31,32].
However, functionally programmed V9/V2 T cells expressing a
semi-invariant TCR already dominate in second trimester foetal
blood, before post-natal microbial exposure [33], therefore arguing
against ligand-driven focussing of the TCR repertoire after birth. As
for murine foetal V5/V1 T cells, the role of putative TCR ligands
in thymic selection of human V9/V2 T cells remains to be inves-
tigated, and further studies are clearly needed to address how  T
cell subsets acquire their TCR and functional speciﬁcities.
2.2. Ligand-dependent peripheral expansion
A change in the TCR repertoire, especially of the variable CDR3ses: How many ligands will it take till we  know? Semin Cell Dev
region, upon infection or in response to other stimuli can be
regarded as evidence of functional involvement of the TCR, and
thus cognate TCR-ligand interaction [34,35]. For instance, human
V9/V2 T cells expand in numerous microbial infections [3,36].
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pig. 1. Different classes of proposed and conﬁrmed  T cell ligands. Examples inclu
-Ad), members of the CD1 family (CD1c, CD1d) that may  or may  not present lipid a
olecules (Skint-1, BTN3A1), other surface-bound proteins (hMSH2, EphA2, annexi
ens’  (HMB-PP, IPP), haptens (cyanine 3, 4-hydroxy-3-nitrophenyl acetyl) and free 
owever, it is not clear whether there is a preferential selection
f certain CDR3 regions upon encountering pathogens, especially
ithin the polyclonal CDR3 repertoire using the V2 gene segment
31,33,37].  T cells also respond towards human cytomegalovirus
CMV), showing striking expansions in the blood of organ trans-
lant recipients [35,38–40]. These expansions are limited to V1+,
3+ and V5+ T cells (often referred to as V2neg T cells) and
ccompanied by restrictions in the CDR3 repertoire, especially of
he CDR3 using the V3 gene segment [38]. While unfocused
olyclonal  TCR repertoires are present in  T cells derived
rom term delivery cord blood [34,40], CDR3 repertoires become
ighly restricted upon congenital CMV  infection in utero, with a
triking enrichment of a public and invariant V8/V1 TCR that
ontains germline-encoded CDR3 and CDR3 [40]. Thus, different
uman  T cell subsets appear to react towards different types of
athogens, and in the case of CMV  infection, substantial changes
n the CDR3 repertoires strongly indicate an involvement of cog-
ate TCR-ligand interactions. Of note, TCR biases have also been
bserved within MHC-restricted  T cell responses, for instance
owards herpes viruses, including CMV  [9,10]. Yet, with only a very
imited number of  TCR ligands and structures deﬁned so far it
emains unclear as to how much these antigen-speciﬁc  TCR
iases compare to the highly skewed  TCR repertoires [34,35,40].
Clonal selection of particular TCRs is a feature of adaptive immu-
ity shared with  T cells and may  indicate the generation of 
 cell memory [34]. Recent studies in mouse models have indeed
rovided evidence for the existence of memory responses by 
 cells [41–45], expanding previous observations in primates and
n cattle [46–48]. In particular, two groups independently demon-
trated an involvement of TCR signalling, presumably as a result of
CR-ligand interactions, in the generation of  T cell memory, with
referential enrichments in the usage of speciﬁc V and V chains
43,44]. Yet, CDR3 sequences were not investigated in these studies,
hus calling for further in-depth analyses of recall responses by 
 cells. Even more, irrespective of the substantial progress in our
nderstanding of changes in the  TCR repertoire during devel-
pment and as a result of homeostatic or infection/stress-relatedPlease cite this article in press as: D. Vermijlen, et al.,  T cell respon
Biol (2018), https://doi.org/10.1016/j.semcdb.2017.10.009
xpansion in the periphery [6,14,34,35,48], there are remarkably
ew examples of  T cell ligands that have been implicated in such
rocesses.ssical MHC  class I (HLA-B*5802, free HLA heavy chain) and class II molecules (I-Ek,
s, MHC  and CD1 related molecules (T10/T22, Qa-1, MICA, EPCR), butyrophilin-like
, soluble proteins (HSV-gI, phycoerythrin, histidyl-tRNA synthetase), ‘phosphoanti-
es (insulin B:9-23 and others).
3. Monomorphic yet diverse ligands: down in the groove?
The unexpected discovery of  T cells in the mid  1980s imme-
diately posed questions as to the nature of the target antigens these
cells recognise. Strikingly, the compounds that have been proposed
or conﬁrmed as  T cell ligands since then span a staggering range
of diverse molecular structures [6,49–52]. Of note, and in stark con-
trast to the highly polymorphic nature of the MHC  class I and class
II complexes that restrict  T cell responses, the vast majority of
 T cell ligands reported thus far are non-polymorphic in nature.
3.1. Recognition of MHC-related molecules
Most research on  T cells so far has used methodologies that
were originally developed and successfully applied to  T cells,
such as immunisations of mice with MHC-mismatched cells, utili-
sation of transfectant APCs expressing deﬁned antigen-presenting
molecules and stainings with antigen-loaded tetramers. Perhaps
not surprisingly, such approaches have led to the identiﬁcation of
 T cell clones and receptors that were reactive with classical and
non-classical MHC  molecules. The corresponding ligands included
structures such as the murine MHC  class II molecules I-Ek and I-Ad
[53,54], as well as the MHC  class Ib molecules T10/T22 [55,56] and
Qa-1 [57] in the mouse, and MICA in humans [58] (Fig. 1).
A number of investigators also characterised CD1-restricted 
T cells in the mouse [59] and in humans [60–66], including a
peculiar T cell clone expressing a / TCR [67]. These reports
have greatly advanced our understanding of  T cell responses in
autoimmunity and infection, and may  be taken as indication that a
considerable proportion of  T cells is reactive to MHC  and MHC-
related molecules [52]. However, it is important to bear in mind
that most of these discoveries were based on preconceived ideas
using deﬁned ligands to identify the corresponding TCRs. Neverthe-
less, the importance of MHC-related molecules has been underlined
further by the recent identiﬁcation of  T cell clones recognising
endothelial protein C receptor (EPCR) [68], HLA-B*5802 [69] andses: How many ligands will it take till we know? Semin Cell Dev
2-microglobulin-free HLA heavy chain [70] (Fig. 1).
Unexpectedly, many  T cell responses to MHC-like molecules
turned out not to be strictly dependent on the presentation of
speciﬁc peptidic or non-peptidic epitopes, unlike the ﬁne-tuned
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phosphoantigens’ that are recognised in the context of BTN3; and different classesPlease cite this article in press as: D. Vermijlen, et al.,  T cell respon
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ecognition of antigens presented to  T cells in the context of
HC  class I and II, MR1  and CD1. This is certainly the case for I-
k [54], T10/T22 [56], MICA [58] and EPCR [68], neither of which
ppear to present antigens to the corresponding  TCRs. Thells. Examples include haptens and peptides that may  bind the  TCR directly;
ds that are presented by CD1c and CD1d.ses: How many ligands will it take till we  know? Semin Cell Dev
case of Qa-1 is less clear, with indirect evidence pointing toward
a possible presentation of antigenic peptides [71]. With regard
to CD1-restricted  T cell responses, a range of phospholipids
and glycolipids has been shown to activate certain  T cell sub-
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ets. Such compounds include phosphomycoketide and dipalmitoyl
hosphatidylcholine in association with CD1c [62,66], as well
s the CD1d-presented molecules cardiolipin in mice [59], and
hosphatidylethanolamine, sulfatide and -galactosylceramide in
umans [61–64,67] (Fig. 2). However, despite strong responses
owards deﬁned phospholipids, most CD1-restricted  T cells also
espond with lower afﬁnities to ‘empty’ CD1 molecules, which may
r may  not present yet unknown self lipids [60,65].
These ﬁndings highlight a remarkable dichotomy between 
 cells and  T cells, where  TCRs recognise truly presented
ntigens in the classical sense while  TCRs may  often respond
o stress-induced ‘empty’ or non-presenting MHC-like molecules.
f note, in contrast to the invariant mouse V5/V1 and V6/V1
CRs and CMV-reactive human V8/V1 TCR described above, most
 TCRs recognising MHC-related molecules appear to contain N
dditions in their CDR3 regions, and the corresponding  T cell
opulations are typically rare [39,53,64].
.2. Antibody-like recognition of surface-associated and soluble
tructures
Early reports on the responsiveness to MHC-like molecules by
ertain  T cell receptors were soon to be paralleled by the dis-
overy of soluble and surface-bound proteins that appeared to bind
irectly to murine and human  TCRs. These ﬁndings in fact led
ome authors to liken the recognition of these potential ligands
y  T cells to the way immunoglobulins recognise their targets
ntigens, which typically constitute three-dimensional epitopes
n larger molecules [72]. The prime example of a protein that is
ecognised directly by  T cells, in the absence of APCs, is the
erpes simplex virus glycoprotein I (HSV-gI) that speciﬁcally acti-
ates a murine V2/V8 T cell clone and may  thus contribute to the
 T cell-mediated protection against HSV infection in mice [73]
Fig. 1). As with HSV-gI speciﬁc  T cells, the responsiveness of
n autoreactive human V3/V2 T cell clone from a polymyositis
esion toward histidyl-tRNA synthetase is directed in an antibody-
ike manner against a conformational epitope of the target antigen
74,75]. Of note, this V3/V2 TCR also cross-reacts with bacterial
minoacyl-tRNA synthetases and E. coli translation initiation factor
.
The human MutS homologue 2 (hMSH2), a nuclear DNA mis-
atch repair protein that can be expressed ectopically on tumour
ells, represents another potential protein ligand for certain human
 T cells [76]. However, as hMSH2 appears to interact with both
he  TCR and NKG2D the precise role of the  TCR in recognis-
ng tumour-associated hMSH2 remains to be resolved. More recent
xamples of potentially stress and infection-regulated self pro-
eins include annexin A2 and ephrin receptor A2 (EphA2), which
re recognised by human V2neg T cell clones derived from CMV
nfected individuals [69,70,77] (Fig. 1).
Finally, phycoerythrin (PE) is a ﬂuorescent molecule in
yanobacteria and red algae that is recognised by a small propor-
ion of  T cells in humans, mice and cattle [78]. Although there
ay  not be a relevant pathogen that produces PE, it is the ﬁrst
escribed ligand that activates  T cells in different species, albeit
ith no apparent sequence similarity between PE-speciﬁc  TCRs
n humans and mice. PE is also the ﬁrst soluble protein that allows
o conveniently track and analyse antigen-speciﬁc  T cells in
he mouse and therefore has enormous potential in experimental
odels.
In addition to larger proteins, some  T cells also recognise
maller molecules, which are believed to bind directly to the TCR,Please cite this article in press as: D. Vermijlen, et al.,  T cell respon
Biol (2018), https://doi.org/10.1016/j.semcdb.2017.10.009
n the absence of APCs [79]. One such candidate is the insulin B:9-23
eptide that is recognised in a dimerised form by murine  T cells,
ossibly as a conformational structure rather than a linearised pep-
ide sequence [80] (Fig. 1). Further self and non-self molecules that PRESS
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have been described to activate human, murine or bovine  T cells
include peptides derived from heat shock proteins, mycobacterial
antigens, tetanus toxin, listeriolysin O and immunoglobulin  light
chain [79,81], as well as the haptens cyanine 3 and 4-hydroxy-3-
nitrophenyl acetyl [82] (Fig. 2). In the majority of cases, especially
for endogenous self peptides, the physiological context leading to
the availability of such soluble molecules as potential ligands for
the  TCR remains to be elucidated.
3.3. The peculiar case of phosphoantigens
The majority of human and primate V9/V2 T cells responds
rapidly to small phosphorylated molecules in vitro, often referred
to as ‘phosphoantigens’ [3]. By far the most potent of these
compounds is the microbial metabolite (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate (HMB-PP), which is produced by many
Gram-positive and Gram-negative bacteria as well as malaria par-
asites and Toxoplasma gondii [3,36] (Fig. 1). Other compounds with
activity on V9/V2 T cells, albeit at levels that can be several
magnitudes above the minimum effective concentration of HMB-
PP, include the ubiquitous metabolites isopentenyl pyrophosphate
(IPP) and dimethylallyl pyrophosphate (DMAPP), which are present
in all prokaryotes and eukaryotes, and related synthetic molecules
such as monoethyl phosphate, bromohydrin pyrophosphate (Phos-
phostim) and a pyrophosphonate analogue of HMB-PP (Picostim)
[3,83] (Fig. 2). Furthermore, the reactivity of V9/V2 T cells toward
aminobisphosphonate drugs such as alendronate, pamidronate and
zoledronate and toward natural and synthetic alkylamines can be
explained by the intracellular accumulation of IPP, DMAPP and
byproducts such as the AMP  conjugate of IPP, ApppI, thereby ren-
dering treated target cells susceptible to recognition by V9/V2 T
cells [83–85]. In addition to its intracellular accumulation, IPP
can be released by zoledronate-treated dendritic cells into the
microenvironment where it becomes available to uptake by other
cells and/or activation of  T cells [83,86]. But are ‘phosphoanti-
gens’ true  TCR ligands? Originally thought to bind to the 
TCR directly [87] and possibly ‘presented’ in the context of acces-
sory proteins including mitochondrial F1-ATPase [88], the recent
discovery of butyrophilin-3 (BTN3) as crucial restricting element
rather points toward an indirect recognition of ‘phosphoantigens’
[89]. Of note, the presence of V9/V2 TCRs may  not be restricted
to higher primates. While being absent in mice, rats, rabbits, cat-
tle and other farm animals, recent ﬁndings suggest that functional
V9/V2 T cells and the reactivity toward ‘phosphoantigens’, along-
side BTN3, may  also be present in alpacas [90]. Such observations
indicate that this microbe-responsive  T cell population may  have
arisen early during evolution of placental mammals and later on
been lost in various groups including rodents [91].
3.4. The role of butyrophilins
Recent studies demonstrated that the BTN3 isoform, BTN3A1,
is essential for V9/V2 T cell responses to HMB-PP, IPP and
aminobisphosphonate-treated cells [89,92]. Initially proposed as
a ‘phosphoantigen’ presenting molecule [92], a growing body
of biochemical and structural evidence identiﬁed an unexpected
‘phosphoantigen’ binding site in the intracellular B30.2 (PRY/SPRY)
domain of BTN3A1 [93–95]. In essence, BTN3A1 appears to convert
a peculiar microbial (HMB-PP) or stress-related (IPP) non-peptidic
signal into a rather common biological phenomenon, namely the
recognition of a cell surface-associated and possibly conforma-
tional epitope that is somehow sensed by V9/V2 T cells [98]ses: How many ligands will it take till we know? Semin Cell Dev
(Fig. 1). While the related isoforms, BTN3A2 and BTN3A3, are some-
how involved in this process [95] the exact mechanism remains
to be deﬁned. BTN3 has consequently replaced ‘phosphoantigens’
as candidate ligand for V9/V2 T cells although it may require
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Fig. 3. Physiological context of  T cell ligand recognition. (A) Recognition of ligands in different physiological settings, ranging from ligand presentation by APCs to
recognition of stressed and infected cells and direct binding of soluble molecules. (B–D) Overlapping recognition of stress and infection related ligands by  T cells and by
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uch  as PE and targets of autoantibodies such as tRNA synthetases (D). BCR/Ig, B cel
ccessory molecules and may  not be recognised directly by the
9/V2 TCR [95–99]. Of note, the immunological role of BTN3A1
ay  extend beyond the regulation of  T cell responses [100,101].
The clear role for BTN3 in driving human V9/V2 T cell
esponses evokes seminal discoveries in other systems amount-
ng to the realisation that the family of butyrophilin-like (BTNL in
umans, Btnl in mice) proteins plays a pivotal part in shaping the
 T cell compartment [102–104]. The best studied Btnl member,
kint-1, is crucially important for the maturation of murine thy-
ocytes and the appearance of V5/V1 DETCs in the epidermis
105,106]. This process requires thymic and epidermal expression
f Skint-1, although it is not clear whether Skint-1 indeed con-
titutes a direct ligand for the V5/V1 TCR [106,107] (Fig. 1).
ntriguingly, there may  also to be a role for Skint-3 and Skint-9 in
odulating DETC function, especially during wound repair [108].
n analogy to the Skint-1 restricted development of V5/V1 T
ells in the mouse epidermis, joint expression of the related pro-
eins Btnl1 and Btnl6 by murine enterocytes is required for the
xtrathymic selection of intestinal V7+ T cells [104]. Similarly,
uman BTNL3 and BTNL8 appear to jointly induce selective TCR-Please cite this article in press as: D. Vermijlen, et al.,  T cell respon
Biol (2018), https://doi.org/10.1016/j.semcdb.2017.10.009
ependent responses by V4+ T cells derived from the human colon
104].ds include, but are not limited to, MHC  and CD1 family members that are recognised
that are recognised by NKG2D on T cells and NK cells (C); and soluble B cell antigens
ptor/immunoglobulin.
These groundbreaking ﬁndings demonstrate that different
butyrophilins inﬂuence the development of speciﬁc  T cell popu-
lations characterised by distinct V chains in mice and in humans,
and identify a fundamental selection principle that is likely to be
applicable to other  T cell subsets and other species. How the dif-
ferent members of the butyrophilin family achieve this remains to
be elucidated, especially as to whether they bind the  TCR directly
or merely constitute critical co-factors. The fact that the majority
of Btnl and BTNL proteins (with the prominent exception of Skint-
1) possess intracellular B30.2 domains also raises the possibility
that as yet unknown accessory molecules are involved in shaping
the  T cell repertoire. B30.2 domains not only sense HMB-PP
and IPP in the case of BTN3A1 but also confer pattern recogni-
tion receptor-like functions to tripartite motif proteins such as
TRIM5 and TRIM21 that are evolutionarily linked to butyrophilins
[103,109a]. While the selection of V7+ T cells by Btnl1/Btnl6
appears to be independent of microbial or food antigens [104], the
self and non-self metabolites and proteins potentially interacting
with butyrophilins clearly deserve closer attention.ses: How many ligands will it take till we  know? Semin Cell Dev
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. Context of ligand expression: by a simple twist of fate
.1. Sensing self, stressed self and non-self
The physiological contexts in which  T cell ligands become
ccessible is key to understand the role of  T cells in the immune
ystem. The chemical and conformational structures that  T cells
espond to cover molecules associated with infection, stressed
issues and tumours as well as with the healthy status, and are
ar more diverse than the relatively narrow range of MHC  and
D1-presented  T cell antigens (Fig. 3A).  T cells sense these lig-
nds by patrolling blood and endothelial and mucosal surfaces for
athogen pattern recognition, and as tissue-resident cells by moni-
oring tissue integrity and vitality [4–6,36]. Pathogens may  actually
nﬂuence this tissue monitoring by targeting  T cell ligands. In
his context, it has recently been shown that human papillomavirus
ncoproteins induce a decrease in epidermal Skint1 expression,
hich is associated with a change in morphology and reduced den-
ity of the associated V5/V1 DETC [109b]. Of note, besides the
CR,  T cells can also express other activating receptors such as
KG2D, NKp30 and CD16 [110], which may  complement or even
eplace TCR signalling in different contexts. For instance, the role
ETCs play in skin immune surveillance is at least in part exerted
ia recognition of stress-induced NKG2D ligands [111]. The rele-
ance of the majority of the  TCR ligands discussed in this review
herefore remains ill-deﬁned, especially since many are only recog-
ised by a very small proportion of the total  T cell population
55,78], or by seemingly rare  T cell clones found in individual
atients [68–70,75].
Non-self molecules sensed by human or murine  T cells
nclude proteinaceous and non-proteinaceous molecules as diverse
s viral HSV-gI [73], algae-derived PE [78], staphylococcal super-
ntigens [112,113], listerolysin and tetanus toxin peptides [79],
ollen-derived phosphatidylethanolamine [61], bacterial cardi-
lipin [59], mycobacterial phosphomycoketide [62] and HMB-PP
36], together with further unidentiﬁed microbial compounds
62,114–116]. Bovine  T cells recognise a range of antigens
erived from Mycobacterium bovis, Leptospira and Anaplasma
lthough the precise role of the  TCR in such responses and
he contribution of WC1  as co-receptor and pattern recognition
eceptor requires further characterisation [81,117,118]. Of note,
ardiolipin may  also derive from the mitochondria of stressed or
amaged host cells [59], and the role of HMB-PP may  be mimicked
y IPP as host-derived self ligand, despite its much lower bioac-
ivity and B30.2 afﬁnity compared to HMB-PP [83,93]. In addition,
 T cells may  respond to both CD1-presented self and non-self
ipids [6,51,52], and there appears to be cross-reactivity between
acterial and mammalian heat shock proteins [79] and aminoacyl-
RNA synthetases [75]. The distinction between self and non-self
ay  thus not be as clear-cut as the above list of ligands insinuates,
hich raises further questions about the physiological context in
hich the corresponding  T cell populations become activated.
It has been proposed that some  TCRs can respond to upreg-
lation of ‘stress proteins’ upon infection, cell transformation or
ther conditions, although examples of such a recognition mode are
imited [4–6,77,119]. Alternatively, ligands may  be constitutively
xpressed, but it is the molecular context that will deﬁne their  T
ell activation potential. For instance, EPCR, the ligand for a  T cell
lone that was expanded in a CMV  infected transplant recipient,
s actually not upregulated upon CMV  infection [68]. CMV  infec-
ion rather appears to result in the induction of other factors that,
ogether with EPCR, form a ‘multi-molecular stress signature’ [68].Please cite this article in press as: D. Vermijlen, et al.,  T cell respon
Biol (2018), https://doi.org/10.1016/j.semcdb.2017.10.009
imilarly, the  TCR of mouse DETCs appears to be continuously
ctivated within the epidermis, suggesting that the corresponding
igand is constitutively expressed by keratinocytes [120]. However,
ellular stress may  provoke changes in the expression and/or the PRESS
opmental Biology xxx (2018) xxx–xxx 7
conformation of the DETC ligand, possibly in conjunction with addi-
tional factors [121]. The importance of further co-factors is also
underlined by the fact that both BTN3A1 and IPP are ubiquitously
expressed by human cells [91,103]. The exact conditions under
which endogenous IPP levels may  exceed a possible threshold for
stressed cells to become stimulatory to V9/V2 T cells whilst pre-
venting autoreactivity toward metabolically active healthy tissues
remain to be deﬁned [3,83]. Clearly,  T cell responses to self
ligands require carefully balanced control mechanisms.
4.2. Implications for pathology and diagnosis
The ability of  T cells to sense structures associated with tissue
stress, transformation and infection has direct consequences in the
clinic. Ligand-dependent  T cell responses may  contribute to pro-
tective immunity against pathogens [73,122] and tumour immune
surveillance [76] but may  also drive inﬂammation-related tissue
damage [123] and autoimmune disease [124,125]. For instance,
IL-17 producing  T cells play a pathogenic role in experimen-
tal models of psoriasis [126,127], and IL-17+ V9/V2 T cells and
common CDR3 sequences have been observed in psoriatic lesions
of patients [128,129], suggesting ligand-driven local recruitment
and/or expansion in the skin.  T cells may  also drive the pathology
in further autoimmune diseases where certain  T subpopulations
are locally enriched, possibly in response to self ligands such as
sulfatide in the case of multiple sclerosis [63,124,130] and histidyl-
tRNA synthetase in the case of polymyositis [74,75]. Vice versa,
pathogens may  target tissue-restricted ligands and thereby affect
the corresponding resident  T cell subset [109b]. In mice deﬁ-
cient in the autoimmune regulator Aire, which functions as a master
transcriptional regulator of thymic gene expression, foetal IL-17+
V6/V1 T cells are increased and contribute to retinal inﬂamma-
tion and degeneration [28]. Also, immunodeﬁcient patients with
mutations in the AIRE gene show elevated percentages of V9/V2 T
cells producing IL-17 [28]. Notwithstanding this apparent contribu-
tion of Aire to immune tolerance by limiting IL-17 production by
 T cells that are generated in early life in both mice and humans
[33,131], it remains unclear whether Aire-dependent effects on
 T cell ligand expression in the thymus play a role in select-
ing autoreactive  T cells [28]. With respect to cancer,  T cells
have well established protective roles in tumour surveillance and
immunotherapy, in particular because of their potent cytotoxic-
ity and IFN- production [4–6]. However, recent studies have also
revealed tumour-promoting functions that are linked to IL-17 pro-
ducing  T cells [109b,132]. How much of such protective or
detrimental responses are driven by  T cell ligands is unclear.
The exquisite speciﬁcity of human V9/V2 T cells for microbial
derived HMB-PP may  be exploitable for diagnostic and prognostic
purposes to help identify the causative pathogen in patient samples
well before conventional culture results become available [133].
Infections caused by HMB-PP producing organisms tend to be asso-
ciated with higher frequencies of V9/V2 T cells than infections
caused by HMB-PP deﬁcient organisms. This is the case in the blood
of patients with acute sepsis [134] but is particularly pronounced
at the site of infection [123,135]. A similar diagnostic potential
may reside within the unique reactivity of human V2neg T cells to
CMV  infections [136–138]. In particular, longitudinal monitoring of
V2neg T cell proﬁles shows promise as prognostic marker for the
prediction of CMV  infection resolution and treatment responses in
kidney transplant recipients [139]. Finally, recent reports suggest
that the expansion of certain V clonotypes in patients with acute
myeloid leukaemia may  correlate with disease outcome [140],ses: How many ligands will it take till we know? Semin Cell Dev
although the speciﬁcity of those  T cell clones remains to be
deﬁned.
It is interesting to note that a signiﬁcant number of  T cell
ligands are also recognised by other immune receptors (Fig. 3B–D).
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ntriguingly, there are cases of autoantibody production and expan-
ion of  T cells possessing the same speciﬁcity, for instance in
atients with multiple sclerosis and polymyositis [63,74,75,124].
uch recognition of the same targets by immunoglobulins and 
 cells may  result from speciﬁc  T cell help to B cells [141],
hich is supported by the observation of a considerable overlap
etween  TCR speciﬁcities and natural antibodies [142]. The sig-
iﬁcance of this redundancy for protection and pathology has not
een addressed as yet.
.3. Implications for therapy and vaccination
A better understanding of  T cell ligands will ultimately guide
he potential application of  T cell based therapies in the clinic.
he monomorphic nature of  T cell ligands and their indepen-
ence of the underlying MHC  haplotype is in fact ideal for vaccine
evelopment and ‘off the shelf’ cellular therapies. However, given
he limited numbers of deﬁned ligands with clear disease rele-
ance and the rare nature of the corresponding  T cell clones,
here is only scarce evidence for a successful stimulation of  T
ell responses with deﬁned ligands in vivo [82,143].
Most progress in this context has been made thanks to the
eactivity of human and primate V9/V2 T cells to ‘phosphoanti-
ens’. In cynomolgus macaques, stimulation with HMB-PP itself,
r with synthetic HMB-PP analogues, induces a strong expansion
f V9/V2 T cells in the blood [144] and their accumulation at
ucosal sites including the lungs of treated animals, and atten-
ates local tuberculosis and plague lesions [122,145]. While these
ndings demonstrate that protective immunity against microbial
athogens can be achieved by directly harnessing  T cells, admin-
stration of ‘phosphoantigens’ alongside mycobacterial antigens
id not have any adjuvant effect in vivo and did not boost con-
ominant vaccine-induced  T cell responses [146]. However,
ctivation of V9/V2 T cells did enhance antibody-dependent
ell-mediated cytotoxicity in cynomolgus macaques treated with
he anti-CD20 depleting antibody rituximab [147]. In humans,
9/V2 T cells can readily be targeted using aminobisphospho-
ates such as zoledronate, most likely via indirect accumulation of
PP and DMAPP in endocytic cells including monocytes, osteoclasts
nd tumour cells [132,148–150]. Alternatively, agonist antibodies
gainst BTN3 may  speciﬁcally sensitise tumour cells to V9/V2 T
ell cytotoxicity although this has thus far only been demonstrated
n murine xenotransplantation models [151], and the safety of anti-
odies targeting ubiquitously expressed BTN3 in the body needs to
e established in humans. These reports provide proof-of-concept
vidence that  T cell responses can be manipulated efﬁciently
f the mode of recognition is known. It will now be interesting to
est whether other ligands are similarly capable of stimulating dis-
inct  T cell subpopulations in vivo. Of note, once activated and/or
xpanded, the anti-tumour potential of  T cells may  at least in
art depend on their recognition of tumour targets via NKG2D and
ther natural killer receptors, and the contribution of  TCR lig-
nds especially in patients receiving adoptively transferred  T
ells is unclear as yet [132,148,149].
In other scenarios, speciﬁc targeting of  T cell ligands in
he clinic may  allow a suppression of excessive  T cell-driven
nﬂammation in infectious or autoimmune diseases. For instance,
nti-BTN3 antibodies effectively abrogate V9/V2 T cell responses
o microbial pathogens and may  thus be able to limit ﬁbrotic
carring of local tissues in vulnerable patient groups [123]. A sim-
lar neutralisation of inappropriate V9/V2 T cell responses may
e achieved by using TCR-speciﬁc variable domains of naturallyPlease cite this article in press as: D. Vermijlen, et al.,  T cell respon
Biol (2018), https://doi.org/10.1016/j.semcdb.2017.10.009
ccurring H chain-only antibodies (nanobodies) [99]. It is thus
onceivable that speciﬁc masking of stress-induced and/or disease-
peciﬁc  T cell ligands can reduce the recognition of target tissues
y pro-inﬂammatory  T cells, which may  block the detrimental PRESS
opmental Biology xxx (2018) xxx–xxx
role these cells can play in autoimmune disorders, transplantation
and ischemia-reperfusion injury [152–154].
5. Outlook: there must be some way out of here
The past few years have seen a wealth of data regarding the TCR
repertoires of distinct  T cell populations in health and disease
and a growing list of conﬁrmed and proposed ligands in differ-
ent species [6,49–52]. Yet, the relevance of the often restricted
TCR usage and the chemical diversity in  T cell ligands remain
largely unclear, and only few structural studies have conﬁrmed
deﬁnite ligand recognition by the TCR [56,63,64]. There are also
open questions pertaining to the speciﬁcity of the  TCR and the
role their ligands play in thymic selection, homeostasis and disease.
Moreover, instead of recognising a single ligand, it is conceivable
that  T cells may  show the same cross-reactivity towards a con-
siderable number of different ligands that is well-established for
 T cells [155]. The existence of multiple speciﬁcities of self and
non-self reactive  TCRs has been discussed before [50], albeit
the implications of such a phenomenon for the thymic selection
of cross-reactive  TCRs and the prevention of potentially auto-
aggressive responses remain to be addressed.
Most importantly, there is no unbiased approach to identify
novel ligands and potential restriction elements. For instance, the
extent of  TCRs that are restricted by MHC-like molecules is not
clear. Whilst a proportion of  T cells can indeed be stained with
tetramers and respond to known and unknown ligands [52], the
identiﬁcation of CD1 restricted  TCRs may  ultimately be the result
of a technological bias and may  not be representative of the 
TCR repertoire as a whole. This caveat notwithstanding, tetramer-
positive  T cells may  actually be enriched in particular tissues
such as the liver and are likely to play a prominent role in vivo
[156]. Another bias may  inevitably be introduced during prolonged
cloning procedures that select for clones with high proliferative
capacity rather than clones with relevant effector function in vivo.
Similarly, approaches to screen infection-associated  TCRs based
on their cross-reactivity with transformed and stressed cells may
eventually only yield self ligands whilst ignoring foreign struc-
tures [68]. The inherent limitations of current methodologies call
for innovative, unsupervised methods that cover the breadth of
possible ligands.
High-throughput sequencing has transformed our ability to
examine antigen receptor repertoires, but this technology is only
starting to be applied to  T cell clonotyping [22,31,34,35,129].
It is expected that in-depth analyses of CDR3 and CDR3 reper-
toires of ex vivo samples will provide a more unbiased insight
into ligand-driven  T cell responses during development and
towards stress-related and infectious stimuli, as well as into
the role of innate-like, invariant and public  TCR sequences
[22,31,33–35,40].  TCRs that are of demonstrable relevance
in vivo can then be subjected to ligand identiﬁcation strategies using
functional blocking antibodies [68] or  TCR tetramers [121,157].
In addition, single-cell sequencing will greatly expand the current
knowledge of the association between particular CDR3 sequences
of a  T cell and its effector functions including programmed
cytokine gene expression [158]. Such approaches will ultimately
aid the discovery of the corresponding TCR ligands.
 T cells have been conserved as a third type of lymphocyte,
alongside  T cells and B cells, since the emergence of jawed verte-
brates 400 million years ago. The dependence of cellular immunity
on a tripartite system of three distinct lymphocyte populationsses: How many ligands will it take till we  know? Semin Cell Dev
goes back even further as it is already found in lampreys [159].
The existence of profound species-speciﬁc differences in TCR reper-
toires, anatomical locations of  T cell subsets and the variable
nature of the ligands they respond may  therefore reﬂect strong
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volutionary pressure and rapid adaption within the  T cell com-
artment. Nevertheless, there are molecules that are recognised by
 T cells across different species and appear to constitute evolu-
ionarily ancient ligands. Such signals include CD1d as restricting
lement for lipid antigens in humans and mice [6]; phycoerythrin
s activator of minor  T cell subsets in humans, mice and cattle
78]; and BTN3/HMB-PP, which may  activate V9/V2 T cells not
nly in humans and other primates but also in alpacas [91]. Further
ork in species other than primates and rodents will help deﬁne
he relevance of functionally overlapping and divergent  T cell
esponses [90,160,161].
In conclusion, the role of  T cells in the immune system has
emained enigmatic over the past three decades, mostly due to the
aucity of ligands identiﬁed so far and their failure to conform to
lassical  T cell-centric models. However, the combination of
igh through-put sequencing, bespoke animal models and access to
ell deﬁned patient cohorts and tissue banks is beginning to shine
ight on one of the remaining blind spots in immunology. Under-
tanding better the molecular nature of  T cell ligands and the
hysiological contexts in which they become available will ﬁnally
llow the integration of  T cell mediated responses into a com-
rehensive view of innate and adaptive immunity. The times they
re a-changin’.
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